Concise review: Therapeutic potential of mesenchymal stem cells for the treatment of acute liver failure and cirrhosis

Stem Cells

Volumn 32, Issue 11, 2014, Pages 2818-2823

  Volarevic, Vladislav ^a   Nurkovic, Jasmin ^b   Arsenijevic, Nebojsa ^a   Stojkovic, Miodrag ^a,c  

^a University of Kragujevac Medical Faculty   (Serbia)

^b State University of Novi Pazar   (Serbia)

^c Spebo Medical   (Serbia)

Author keywords

Acute liver failure; Cirrhosis; Mesenchymal stem cell; Therapy

Indexed keywords

ANIMALS; CELL- AND TISSUE-BASED THERAPY; CYTOLOGY; FIBROSIS; HUMANS; LIVER FAILURE, ACUTE; LIVER REGENERATION; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; PHYSIOLOGY;

ANIMALS; CELL- AND TISSUE-BASED THERAPY; FIBROSIS; HUMANS; LIVER FAILURE, ACUTE; LIVER REGENERATION; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS;

EID: 84907895309     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.1818     Document Type: Review

References (47)

1. Zhang Z, Wang FS,. Stem cell therapies for liver failure and cirrhosis. J Hepatol 2013; 59: 183-185.
2. Volarevic V, Ljujic B, Stojkovic P, et al. Human stem cell research and regenerative medicine-Present and future. Br Med Bull 2011; 99: 155-168.
3. Volarevic V, Arsenijevic N, Lukic ML, et al. Concise review: Mesenchymal stem cell treatment of the complications of diabetes mellitus. Stem Cells 2011; 29: 5-10.
4. Volarevic V, Al-Qahtani A, Arsenijevic N, et al. Interleukin-1 receptor antagonist (IL-1Ra) and IL-1Ra producing mesenchymal stem cells as modulators of diabetogenesis. Autoimmunity 2010; 43: 255-263.
5. Shu SN, Wei L, Wang JH, et al. Hepatic differentiation capability of rat bone marrow-derived mesenchymal stem cells and hematopoietic stem cells. World J Gastroenterol 2004; 10: 2818-2822.
6. Lange C, Bassler P, Lioznov MV, et al. Hepatocytic gene expression in cultured rat mesenchymal stem cells. Transplant Proc 2005; 37: 276-279.
7. Lange C, Bassler P, Lioznov MV, et al. Liver-specific gene expression in mesenchymal stem cells is induced by liver cells. World J Gastroenterol 2005; 11: 4497-4504.
8. Luk JM, Wang PP, Lee CK, et al. Hepatic potential of bone marrow stromal cell: Development of in vitro co-culture and intra-portal transplantation models. J Immunol Methods 2005; 305: 39-47.
9. Lee KD, Kuo TKC, Whang-Peng J, et al. In vitro hepatic differentiation of human mesenchymal stem cells. Hepatology 2004; 40: 1275-1284.
10. Seo MJ, Suh SY, Bae YC, et al. Differentiation of human adipose stromal cells into hepatic lineage in vitro and in vivo. Biochem Biophys Res Commun 2005; 328: 258-264.
11. Banas A, Teratani T, Yamamoto Y, et al. Rapid hepatic fate specification of adipose-derived stem cells and their therapeutic potential for liver failure. J Gastroenterol Hepatol 2009; 24: 70-77.
12. Zheng YB, Gao ZL, Xie C, et al. Characterization and hepatogenic differentiation of mesenchymal stem cells from human amniotic fluid and human bone marrow: A comparative study. Cell Biol Int. 2008; 32: 1439-1448.
13. Ishkitiev N, Yaegaki K, Calenic B, et al. Deciduous and permanent dental pulp mesenchymal cells acquire hepatic morphologic and functional features in vitro. J Endod 2010; 36: 469-474.
14. Ling L, Ni Y, Wang Q, et al. Transdifferentiation of mesenchymal stem cells derived from human fetal lung to hepatocyte-like cells. Cell Biol Int 2008; 32: 1091-1098.
15. Ke Z, Zhou F, Wang L, et al. Down-regulation of Wnt signaling could promote bone marrow-derived mesenchymal stem cells to differentiate into hepatocytes. Biochem Biophys Res Commun 2008; 367: 342-348.
16. Lam SP, Luk JM, Man K, et al. Activation of interleukin-6-induced glycoprotein 130/signal transducer and activator of transcription 3 pathway in mesenchymal stem cells enhances hepatic differentiation, proliferation, and liver regeneration. Liver Transpl 2010; 16: 1195-1206.
17. Parekkadan B, van Poll D, Suganuma K, et al. Mesenchymal stem cell-derived molecules reverse fulminant hepatic failure. PLoS One 2007; e941: 1-6.
18. Ishikawa T, Terai S, Urata Y, et al. Administration of fibroblast growth factor 2 in combination with bone marrow transplantation synergistically improves carbon-tetrachloride-induced liver fibrosis in mice. Cell Tissue Res 2007; 327: 463-470.
19. Kharaziha P, Hellstrom PM, Noorinayer B, et al. Improvement of liver function in liver cirrhosis patients after autologous mesenchymal stem cell injection: A phase I-II clinical trial. Eur J Gastroenterol Hepatol 2009; 21: 1199-1205.
20. Xagorari A, Siotou E, Yiangou M, et al. Protective effect of mesenchymal stem cell-conditioned medium on hepatic cell apoptosis after acute liver injury. Int J Clin Exp Pathol 2013; 6: 831-840.
21. Jang YO, Kim YJ, Baik SK, et al. Histological improvement following administration of autologous bone marrow-derived mesenchymal stem cells for alcoholic cirrhosis: A pilot study. Liver Int 2013; 34: 1-9.
22. Zhu X, He B, Zhou X, et al. Effects of transplanted bone-marrow-derived mesenchymal stem cells in animal models of acute hepatitis. Cell Tissue Res 2013; 351: 477-486.
23. Volarevic V, Mitrovic M, Milovanovic M, et al. Protective role of IL-33/ST2 axis in Con A-induced hepatitis. J Hepatol 2011; 56: 26-33.
24. Volarevic V, Milovanovic M, Ljujic B, et al. Galectin-3 deficiency prevents concanavalin A-induced hepatitis in mice. Hepatology 2012; 55: 1954-1964.
25. Bansal MB, Kovalovich K, Gupta R, et al. Interleukin-6 protects hepatocytes from CCl4-mediated necrosis and apoptosis in mice by reducing MMP-2expression. J Hepatol 2005; 42: 548-556.
26. Kovalovich K, Li W, DeAngelis R, et al. Interleukin-6 protects against Fas-mediated death by establishing acritical level of anti-apoptotic hepatic proteins FLIP, Bcl-2, and Bcl-XL. J Biol Chem 2001; 276: 26605-26613.
27. Parekkadan B, van Poll D, Megeed Z, et al. Immunomodulation of activated hepatic stellate cells by mesenchymal stem cells. Biochem Biophys Res Commun 2007; 363: 247-252.
28. van Poll D, Parekkadan B, Cho CH, et al. Mesenchymal stem cell-derived molecules directly modulate hepatocellular death and regeneration in vitro and in vivo. Hepatology 2008; 47: 1634-1643.
29. Fang B, Shi M, Liao L, et al. Systemic infusion of FLK1(+) mesenchymal stem cells ameliorate carbon tetrachloride-induced liver fibrosis in mice. Transplantation 2004; 78: 83-88.
30. Lin N, Hu K, Chen S, et al. Nerve growth factor-mediated paracrine regulation of hepatic stellate cells by multipotent mesenchymal stromal cells. Life Sci 2009; 85: 291-295.
31. Oyagi S, Hirose M, Kojima M, et al. Therapeutic effect of transplanting HGF-treated bone marrow mesenchymal cells into CCl4-injured rats. J Hepatol 2006; 44: 742-748.
32. Higashiyama R, Inagaki Y, Hong YY, et al. Bone marrow-derived cells express matrix metalloproteinases and contribute to regression of liver fibrosis in mice. Hepatology 2007; 45: 213-222.
33. Li T, Zhu J, Ma K, et al. Autologous bone marrow-derived mesenchymal stem cell transplantation promotes liver regeneration after portal vein embolization in cirrhotic rats. J Surg Res 2013; 184: 1161-1173.
34. Mohamadnejad M, Alimoghaddam K, Mohyeddin-Bonab M, et al. Phase 1 trial of autologous bone marrow mesenchymal stem cell transplantation in patients with decompensated liver cirrhosis. Arch Iran Med 2007; 10: 459-466.
35. Kharaziha P, Hellström PM, Noorinayer B, et al. Improvement of liver function in liver cirrhosis patients after autologous mesenchymal stem cell injection: A phase I-II clinical trial. Eur J Gastroenterol Hepatol 2009; 21: 1199-1205.
36. Amer ME, El-Sayed SZ, El-Kheir WA, et al. Clinical and laboratory evaluation of patients with end-stage liver cell failure injected with bone marrow-derived hepatocyte-like cells. Eur J Gastroenterol Hepatol 2011; 23: 936-941.
37. Peng L, Xie DY, Lin BL, et al. Autologous bone marrow mesenchymal stem cell transplantation in liver failure patients caused by hepatitis B: Short-term and long-term outcomes. Hepatology 2011; 54: 820-828.
38. El-Ansary M, Abdel-Aziz I, Mogawer S, et al. Phase II trial: Undifferentiated versus differentiated autologous mesenchymal stem cells transplantation in Egyptian patients with HCV induced liver cirrhosis. Stem Cell Rev 2012; 8: 972-981.
39. Amin MA, Sabry D, Rashed LA, et al. Short-term evaluation of autologous transplantation of bone marrow-derived mesenchymal stem cells in patients with cirrhosis: Egyptian study. Clin Transplant 2013; 27: 607-612.
40. Meier RP, Müller YD, Morel P, et al. Transplantation of mesenchymal stem cells for the treatment of liver diseases, is there enough evidence? Stem Cell Res 2013; 11: 1348-1364.
41. di Bonzo LV, Ferrero I, Cravanzola C, et al. Human mesenchymal stem cells as a two-edged sword in hepatic regenerative medicine: Engraftment andhepatocyte differentiation versus profibrogenic potential. Gut 2008; 57: 223-231.
42. Baertschiger RM, Serre-Beinier V, Morel P, et al. Fibrogenic potential of human multipotent mesenchymal stromal cells in injured liver. PLoS One 2009; 4: e6657.
43. Aurich H, Sgodda M, Kaltwasser P, et al. Hepatocyte differentiation of mesenchymal stem cells from human adipose tissue in vitro promotes hepatic integration in vivo. Gut 2009; 58: 570-581.
44. Mohamadnejad M, Alimoghaddam K, Bagheri M, et al. Randomized placebo-controlled trial of mesenchymal stem cell transplantation in decompensated cirrhosis. Liver Int 2013; 33: 1490-1496.
45. Espejel S, Roll GR, McLaughlin KJ, et al. Induced pluripotent stem cell-derived hepatocytes have the functional and proliferative capabilities needed for liver regeneration in mice. J Clin Invest 2010; 120: 3120-3126.
46. Garcia S, Bernad A, Martín MC, et al. Pitfalls in spontaneous in vitro transformation of human mesenchymal stem cells. Exp Cell Res 2010; 316: 1648-1650.
47. Pan Q, Fouraschen SM, de Ruiter PE, et al. Detection of spontaneous tumorigenic transformation during culture expansion of human mesenchymal stromal cells. Exp Biol Med (Maywood) 2014; 239: 105-115.